HAVN Life Sciences Inc.

HAVN

CA4196213058

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 02:12:37 2023-11-09 pm EST			5-day change	1st Jan Change
0.03 ^CAD	-.--%		+20.00%	-.--%

2023	HAVN Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2023	CI
2023	HAVN Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2022	CI

Havn Life Sciences Inc. Announces Departure of Mr. Tim Laidler as A Director

September 29, 2022 at 04:56 pm EDT

HAVN Life Sciences Inc. announced the departure of Mr. Tim Laidler as a director on the Board of the Company, effective September 29, 2022.

Latest news about HAVN Life Sciences Inc.

HAVN Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2023	23-04-04	CI
HAVN Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2022	23-01-26	CI
HAVN Life Sciences Inc. Announces Retail Listing with Loblaws Company Ltd	22-10-27	CI
HAVN Life Sciences Inc. Announces Board Changes	22-10-14	CI
HAVN Life Sciences Inc. Announces CFO Changes	22-10-14	CI
Havn Life Sciences Inc. Announces Departure of Mr. Tim Laidler as A Director	22-09-29	CI
HAVN Life Sciences Inc. Reports Earnings Results for the First Quarter Ended July 31, 2022	22-09-27	CI
HAVN Life Sciences Says Board Putting Together Restructuring Plan	22-09-20	MT
HAVN Life Sciences Inc. Auditor Raises 'Going Concern' Doubt	22-08-28	CI
HAVN Life Sciences Inc. Reports Earnings Results for the Full Year Ended April 30, 2022	22-08-28	CI
HAVN Life Sciences Completes First Tranche of Financing Commitment by Alpha Blue Ocean, Reports Warrant Amendments	22-08-19	MT
HAVN Life to Undertake Share Consolidation	22-07-29	MT
HAVN Life Shares Down 8.3% as Details $9 Million Financing Arrangement	22-07-22	MT
HAVN Life Sciences Inc. announced that it expects to receive CAD 9 million in funding from Alpha Blue Ocean Investment Group	22-07-20	CI
HAVN Life Sciences Inc. Enters Supply Agreement with MPB Group Inc	22-06-28	CI
HAVN Life Sciences Inc. Announces Board Changes	22-06-14	CI
HAVN Life Signs Supply Agreement with Licenced Jamaican Cannabis Producer, Green Stripe Naturals	22-06-07	MT
HAVN Life Sciences Inc. Signs Supply Agreement with Licenced Jamaican Cannabis Producer, Green Stripe Naturals Ltd	22-06-07	CI
HAVN Life Sciences Inc. Secures Supply Agreement with Atman Retreats	22-05-10	CI
HAVN Life Ships First Order of Natural Health Products to Australia's Woke Pharmaceuticals	22-05-02	MT
Havn Life Ships First White Label Order to Distribution Partner Woke Pharmaceuticals in Australia	22-05-02	CI
HAVN Life Sciences Inc. Launches the Brain Evolve Series	22-04-13	CI
HAVN Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2022	22-04-01	CI
HAVN Life Sciences Inc. Expands Supply Agreement with Mycotopia Therapies Inc	22-03-22	CI
HAVN Life Announces Distribution Deal with Jonluca Enterprises Inc	22-03-15	CI

HAVN Life Sciences Inc. is a Canada-based biotechnology company. The Company is engaged in the scientific research and development of psychopharmacological and natural health care products. It is focused on standardizing extraction of psychoactive compounds, the development of natural health products, and developing mental health treatments to support brain health and enhance the capabilities of the mind. The Company has two business divisions: HAVN Labs and HAVN Retail. The HAVN Labs division is engaged in the development of research protocols to cover the production of Psilocybe spp. Through its research division, HAVN Labs, it has developed an end-to-end supply chain of GMP naturally derived psychedelic compounds for research. The HAVN Retail division formulates and sells natural health products (NHPs) using compounds. It offers a full range of mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.

Sector

Biotechnology & Medical Research

Calendar

2024-09-19 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HAVN LIFE SCIENCES INC.	-.--%	627K
MODERNA, INC.	+26.28%	48.09B
IQVIA HOLDINGS INC.	-3.99%	40.43B
LONZA GROUP AG	+45.32%	40.62B
CELLTRION, INC.	-6.20%	28.36B
ICON PUBLIC LIMITED COMPANY	+6.36%	24.89B
ALNYLAM PHARMACEUTICALS, INC.	-21.47%	19.01B
MEDPACE HOLDINGS, INC.	+27.58%	12.09B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.75%	11.8B
BIO-TECHNE CORPORATION	-2.02%	11.88B